Overview

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19
Phase:
Phase 3
Details
Lead Sponsor:
Ology Bioservices
Collaborators:
Chemical, Biological, Radiological, and Nuclear Medical
Pharm-Olam, LLC
Treatments:
Adalimumab